Morphological and Growth Altering Effects of Cisplatin in C. Albicans Using Fluorescence Microscopy

Overview

Journal Ann Clin Microbiol Antimicrob

Publisher Biomed Central

Specialties Infectious Diseases
Microbiology

Date 2005 Apr 27

PMID 15850483

Citations 4

Authors

Chandrasekhar Kesavan

Malathi Raghunathan

Natarajan Ganesan

Affiliations

Soon will be listed here.

Abstract

Changes in morphology and growth curve of Candida albicans in response to treatment by Cisplatin has been studied using fluorescence staining with ethidium bromide. Treatment with Cisplatin was found to markedly inhibit hyphae and ovoid growth as revealed by ethidium bromide staining of drug treated cells. These changes were concomitant with inhibitory effects on the growth curve with respect to untreated cells. Presence of Cisplatin not only caused suppression in the limiting values in the growth curve, but also caused a slight left shift in the EC50 values. Some of the ovoid cells undergoing poisoning with cisplatin were found to be unusually enlarged before undergoing their natural fate thus suggesting formation of similar cytotoxic end products with DNA.

Citing Articles

Different wavelengths of laser: are they significant for treatment of denture stomatitis?: an in-vitro study.

Salah El-Din M, El-Sharkawy A, Abdelrahman H, Hanno K BMC Oral Health. 2024; 24(1):71.

PMID: 38212756 PMC: 10782685. DOI: 10.1186/s12903-023-03845-8.

11g, a Potent Antifungal Candidate, Enhances Immunogenicity by Unmasking β-Glucan in Fungal Cell Wall.

Huang X, Liu Y, Ni T, Li L, Yan L, An M Front Microbiol. 2020; 11:1324.

PMID: 32695076 PMC: 7338940. DOI: 10.3389/fmicb.2020.01324.

Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans.

Routh M, Chauhan N, Karuppayil S Braz J Microbiol. 2014; 44(3):855-9.

PMID: 24516452 PMC: 3910200. DOI: 10.1590/s1517-83822013000300029.

Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Chen S, Lewis R, Kontoyiannis D Virulence. 2011; 2(4):280-95.

PMID: 21701255 PMC: 3173675. DOI: 10.4161/viru.2.4.16764.

References

Wall S, Jones B . Gastrointestinal tract in the immunocompromised host: opportunistic infections and other complications. Radiology. 1992; 185(2):327-35. DOI: 10.1148/radiology.185.2.1410332. View

Sarachek A, Henderson L, Wilkens W . Evaluation of the genotoxic spectrum of cisplatin for Candida albicans. Microbios. 1992; 72(292-293):183-201. View

Otto A, Paddenberg R, Schubert S, Mannherz H . Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol. 1996; 122(10):603-12. DOI: 10.1007/BF01221192. View

Miletti K, Leibowitz M . Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition. Antimicrob Agents Chemother. 2000; 44(4):958-66. PMC: 89798. DOI: 10.1128/AAC.44.4.958-966.2000. View

Watanabe T, Takano M, Ogasawara A, Mikami T, Kobayashi T, Watabe M . Anti-Candida activity of a new platinum derivative. Antimicrob Agents Chemother. 2000; 44(10):2853-4. PMC: 90162. DOI: 10.1128/AAC.44.10.2853-2854.2000. View

Chandrasekar K, Shyla J, Malathi R . Can antitumor platinum compounds be effective against Candida albicans?--A screening assay using disk diffusion method. J Clin Microbiol. 2001; 38(10):3905. PMC: 87509. DOI: 10.1128/JCM.38.10.3905-3905.2000. View

Sarachek A, Henderson L . Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents. Mycoses. 1991; 34(3-4):177-82. DOI: 10.1111/j.1439-0507.1991.tb00640.x. View

Calderone R, Fonzi W . Virulence factors of Candida albicans. Trends Microbiol. 2001; 9(7):327-35. DOI: 10.1016/s0966-842x(01)02094-7. View

St Georgiev V . Membrane transporters and antifungal drug resistance. Curr Drug Targets. 2001; 1(3):261-84. DOI: 10.2174/1389450003349209. View

10.

Bernhardt H, Knoke M, Bernhardt J . Changes in Candida albicans colonization and morphology under influence of voriconazole. Mycoses. 2003; 46(9-10):370-4. DOI: 10.1046/j.0933-7407.2003.00908.x. View

11.

Aoki S, Ito-Kuwa S, Nakamura Y, Masuhara T . Mitochondrial behaviour during the yeast-hypha transition of Candida albicans. Microbios. 1989; 60(243):79-86. View

12.

Moussa N, Ghannoum M, Whittaker P, Quraman S . Effects of cisplatin and two novel palladium complexes on Candida albicans. Microbios. 1990; 62(252-253):165-78. View

13.

Saral R . Candida and Aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis. 1991; 13(3):487-92. DOI: 10.1093/clinids/13.3.487. View

14.

Hopfer R, Sparks S, Cox G . The use of flow cytometry as a tool for monitoring filament formation of fungi. Med Mycol. 2001; 39(1):103-7. DOI: 10.1080/mmy.39.1.103.107. View